Castration-Resistant Prostate Cancer: From New Pathophysiology to New Treatment
- 1 February 2014
- journal article
- research article
- Published by Elsevier in European Urology
- Vol. 65 (2) , 289-299
Abstract
No abstract availableKeywords
Funding Information
- Novartis
- Janssen Pharmaceutica
- Amgen
- Bayer
- Astellas Pharma Canada
This publication has 48 references indexed in Scilit:
- Increased Survival with Enzalutamide in Prostate Cancer after ChemotherapyNew England Journal of Medicine, 2012
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced CancerNew England Journal of Medicine, 2012
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in CancerNew England Journal of Medicine, 2012
- Synthesis and biological evaluations of putative metabolically stable analogs of VN/124-1 (TOK-001): Head to head anti-tumor efficacy evaluation of VN/124-1 (TOK-001) and abiraterone in LAPC-4 human prostate cancer xenograft modelSteroids, 2011
- Abiraterone and Increased Survival in Metastatic Prostate CancerNew England Journal of Medicine, 2011
- Sipuleucel-T Immunotherapy for Castration-Resistant Prostate CancerNew England Journal of Medicine, 2010
- Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008International Journal of Cancer, 2010
- Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1–2 studyThe Lancet, 2010
- Anti-androgens and androgen-depleting therapies in prostate cancer: new agents for an established targetThe Lancet Oncology, 2009
- A role for the androgen-receptor in clinically localized and advanced prostate cancerBest Practice & Research Clinical Endocrinology & Metabolism, 2008